​

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMLX Stock Forecast

Amylyx Pharmaceuticals (AMLX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $18.00, with a high of $25.00 and a low of $10.00. This represents a 27.03% increase from the last price of $14.17.

- $5 $10 $15 $20 $25 High: $25 Avg: $18 Low: $10 Last Closed Price: $14.17

AMLX Stock Rating

Amylyx Pharmaceuticals stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

AMLX Price Target Upside V Benchmarks

TypeNameUpside
StockAmylyx Pharmaceuticals27.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts125
Avg Price Target$19.00$22.00$16.40
Last Closing Price$14.17$14.17$14.17
Upside/Downside34.09%55.26%15.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25181--10
Sep, 25181--10
Aug, 25181--10
Jul, 25171--9
Jun, 25151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2025Joel BeattyRobert W. Baird$19.00$15.7920.33%34.09%
Sep 15, 2025Seamus FernandezGuggenheim$25.00$11.85110.97%76.43%
Jun 24, 2025Seamus FernandezGuggenheim$17.00$6.41165.21%19.97%
May 06, 2025Marc GoodmanLeerink Partners$10.00$4.65115.05%-29.43%
Nov 18, 2024Joel BeattyRobert W. Baird$11.00$4.76131.09%-22.37%
Oct 23, 2024Geoff MeachamBank of America Securities$10.00$4.53120.75%-29.43%
Oct 18, 2024Andrew FeinH.C. Wainwright$8.00$3.92104.08%-43.54%
Oct 18, 2024Marc GoodmanLeerink Partners$4.00$3.922.04%-71.77%
May 14, 2024Graig SuvannavejhMizuho Securities$3.00$1.8264.84%-78.83%
Apr 11, 2024Joel BeattyRobert W. Baird$3.00$2.4621.95%-78.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2025CitigroupBuyBuyhold
Sep 15, 2025GuggenheimBuyBuyhold
Jun 24, 2025JefferiesHoldinitialise
Oct 23, 2024Bank of America SecuritiesBuyupgrade
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Leerink PartnersMarket PerformMarket Performhold
Jul 12, 2024Goldman SachsUnderperformUnderperformhold
Jul 11, 2024Goldman SachsNeutralNeutralhold
Jun 24, 2024H.C. WainwrightBuyBuyhold
May 10, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.52$-2.98$0.73$-4.43----
Avg Forecast$-15.35$-3.49$0.90$-4.29$-1.61$-1.38$-1.20$-1.00
High Forecast$-15.35$-3.49$0.98$-4.12$-1.08$-0.72$-0.38$-1.00
Low Forecast$-15.35$-3.49$0.79$-4.39$-1.87$-2.43$-2.54$-1.00
Surprise %-90.10%-14.61%-18.89%3.26%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$285.00K$22.23M$380.79M$87.37M----
Avg Forecast$528.33K$4.42M$379.74M$87.94M$114.53M$215.00K$6.33M$29.14M
High Forecast$528.36K$4.42M$382.02M$87.96M$114.53M$215.00K$6.33M$29.14M
Low Forecast$528.30K$4.42M$377.56M$87.92M$114.53M$215.00K$6.33M$29.14M
Surprise %-46.06%402.66%0.27%-0.65%----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-87.88M$-198.38M$49.27M$-301.74M----
Avg Forecast$-1.07B$-244.32M$61.82M$-297.81M$-103.83M$-83.57M$-70.33M$-70.17M
High Forecast$-1.07B$-244.29M$68.69M$-288.36M$-75.69M$-50.39M$-26.60M$-70.17M
Low Forecast$-1.07B$-244.33M$54.95M$-307.26M$-131.14M$-170.08M$-177.78M$-70.17M
Surprise %-91.82%-18.80%-20.30%1.32%----

AMLX Forecast FAQ

Is Amylyx Pharmaceuticals stock a buy?

Amylyx Pharmaceuticals stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Amylyx Pharmaceuticals is a favorable investment for most analysts.

What is Amylyx Pharmaceuticals's price target?

Amylyx Pharmaceuticals's price target, set by 11 Wall Street analysts, averages $18 over the next 12 months. The price target range spans from $10 at the low end to $25 at the high end, suggesting a potential 27.03% change from the previous closing price of $14.17.

How does Amylyx Pharmaceuticals stock forecast compare to its benchmarks?

Amylyx Pharmaceuticals's stock forecast shows a 27.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Amylyx Pharmaceuticals over the past three months?

  • October 2025: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Amylyx Pharmaceuticals’s EPS forecast?

Amylyx Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.61, marking a -63.66% decrease from the reported $-4.43 in 2024. Estimates for the following years are $-1.38 in 2026, $-1.2 in 2027, and $-1 in 2028.

What is Amylyx Pharmaceuticals’s revenue forecast?

Amylyx Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $114.53M, reflecting a 31.09% increase from the reported $87.37M in 2024. The forecast for 2026 is $215K, followed by $6.33M for 2027, and $29.14M for 2028.

What is Amylyx Pharmaceuticals’s net income forecast?

Amylyx Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-104M, representing a -65.59% decrease from the reported $-302M in 2024. Projections indicate $-83.569M in 2026, $-70.333M in 2027, and $-70.166M in 2028.